title: Fabry disease and the skin: data from FOS, the Fabry outcome survey.
abstract: BACKGROUND
  Fabry disease (also known as Anderson-Fabry disease) is a rare, X-linked lysosomal storage disorder that is characterized by accumulation of globotriaosylceramide throughout a range of tissues in the body.
  
  
  OBJECTIVE
  To ascertain the prevalence and nature of cutaneous manifestations in patients with Fabry disease and to relate these to the severity of systemic manifestations of the disease.
  
  
  METHODS
  We have documented the dermatological features of this disease with reference to data from 714 patients (345 males, 369 females) registered on the Fabry Outcome Survey (FOS), a multicentre European database.
  
  
  RESULTS
  We confirm that the commonest disease manifestation is angiokeratoma. Overall, 78% of males and 50% of females had one or more dermatological abnormality, the commonest being angiokeratoma (66% males, 36% females), hypohidrosis (53% males, 28% females), telangiectasia (23% males, 9% females) and lymphoedema (16% males, 6% females). We demonstrate for the first time that the presence of cutaneous vascular lesions correlates with the severity of the systemic manifestations of the disease (pain, renal failure, cardiac disease, premature cerebrovascular disease) as assessed by a severity scoring system. Although the condition is X linked, there is a surprisingly high prevalence of abnormalities in females.
  
  
  CONCLUSIONS
  The FOS database is a useful epidemiological tool in establishing the variety and relevance of cutaneous manifestations in Fabry disease. The present study confirms that the presence of dermatological manifestations appears to be a marker of greater severity of systemic disease, which emphasizes the importance of the dermatological assessment of these patients.
authors.affiliation: Department of Dermatology, Royal Free Hospital, London NW3 2QG, UK. cate.orteu@royalfree.nhs.uk
authors.forename: C H
authors.initials: CH
authors.lastname: Orteu
authors.forename: T
authors.initials: T
authors.lastname: Jansen
authors.forename: O
authors.initials: O
authors.lastname: Lidove
authors.forename: R
authors.initials: R
authors.lastname: Jaussaud
authors.forename: D A
authors.initials: DA
authors.lastname: Hughes
authors.forename: G
authors.initials: G
authors.lastname: Pintos-Morell
authors.forename: U
authors.initials: U
authors.lastname: Ramaswami
authors.forename: R
authors.initials: R
authors.lastname: Parini
authors.forename: G
authors.initials: G
authors.lastname: Sunder-Plassman
authors.forename: M
authors.initials: M
authors.lastname: Beck
authors.forename: A B
authors.initials: AB
authors.lastname: Mehta
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000794:Angiokeratoma / Q000453:epidemiology / Q000209:etiology / Q000473:pathology; D002648:Child; D005060:Europe / Q000453:epidemiology; D000795:Fabry Disease / Q000150:complications* / Q000453:epidemiology / Q000473:pathology; D005260:Female; D006801:Humans; D007007:Hypohidrosis / Q000453:epidemiology / Q000209:etiology; D008209:Lymphedema / Q000453:epidemiology / Q000209:etiology; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012720:Severity of Illness Index; D012737:Sex Factors; D012871:Skin Diseases / Q000453:epidemiology / Q000209:etiology*; D012878:Skin Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000473:pathology; D013684:Telangiectasis / Q000453:epidemiology / Q000209:etiology / Q000473:pathology